在早期癌症预防临床试验中对假设与观察效应大小进行系统审查和聚合分析
Jens Eickhoff1, Jen Zaborek1, Guanhua Chen1
1Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Cancer prevention research (Philadelphia, Pa.)
|May 31, 2023
概括
早期癌症预防试验往往无法检测干预效应. 聚合分析显示,观察到的效应大小明显小于假设,需要仔细的试验设计和样本大小规划.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 预防医学 预防医学
背景情况:
- 早期癌症预防试验的目的是评估预防剂的安全性,耐受性,可行性和疗效信号.
- 许多早期化学预防试验没有检测到假设的干预效应,导致识别有前途的药物的潜在失败.
- 了解假设和观察到的效果大小之间的差异对于优化试验设计和资源分配至关重要.
结论:
- 早期癌症化疗预防试验经常产生比最初假设的更小的观察效果大小.
- 准确的样本大小计算必须平衡可检测效应大小与现实的人口积累,以实现成本效益.
- 精心规划研究设计,主要终点和样本大小对于成功的早期化疗预防试验至关重要.
相关概念视频
Hazard Ratio
170
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
170
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
150
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
150
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Comparing the Survival Analysis of Two or More Groups
229
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
229
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K


